BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sanofi-Aventis (France) (SASY.PA) To Pay $360 Million To Japan's Taiho Pharmaceutical To License S-1 Oral Anticancer Agent


7/5/2006 1:49:51 PM

(RTTNews) - Sanofi-Aventis announced that it has signed an agreement with Japan's Taiho Pharmaceutical Co. Ltd. for the rights to develop and market an oral, pyrimidine fluoride derived anticancer agent, S-1, a proprietary product.

The Paris-based Sanofi-Aventis said that it will pay Taiho about US$360 million upfront and milestone payments upon this oral anticancer agent S-1.

As per the deal, Sanofi-Aventis will lead and fund the development and commercialization of the product worldwide, except in Japan and in certain Asian countries.

The oral anticancer agent S-1 is currently in Phase III stage in Europe, US and other countries.

S-1 has been prescribed and marketed in Japan since 1999 for the treatment of gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, inoperable or recurrent breast cancer.

SNY closed Monday's trading session at $49.23, up 53 cents or 1.09%.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES